The Treatment of Moderate-to-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics

Seminars in Cutaneous Medicine and Surgery

Volumn 29, Issue 1, 2010, Pages 28-34

  Levine, Danielle ^a   Strober, Bruce E ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BCG VACCINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; METHOTREXATE; PARACETAMOL; PLACEBO; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLOGICAL THERAPY; BLOOD CLOTTING DISORDER; BREAST CANCER; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION; INJECTION SITE REACTION; LIVER CIRRHOSIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; LYMPHOMA; MELANOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PHARYNGITIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTMARKETING SURVEILLANCE; PSORIASIS; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; STOMACH ADENOCARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULIN TEST; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DRUG MONITORING; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS;

EID: 77951594760     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2010.02.003     Document Type: Review

References (54)

1. Cooper J.C., Morgan G., Susanne H., et al. Alefacept selectively promotes NK cell medicated deletion of CD450RO1 human T cells. Eur J Immunol 33 (2003) 666-675
2. Krueger G.G., Papp K.A., Stough D.B., et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
3. Lebwohl M., Christophers E., Langley R., et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
4. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
5. Gribetz C.H., Blum R., Brady C., et al. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 53 (2005) 73-75
6. Gordon K.B., Vaishnaw A.K., O'Gorman J., et al. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 139 (2003) 1563-1570
7. Ortonne J.P., Lebwohl M., and Em G.C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 13 (2003) 117-123
8. Weinberg J.M. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 25 (2003) 2487-2505
9. Krell J., Bagel J., and Coynik D. Assessment and tracking of longterm alefacept safety (ATLAS): analysis of data from approximately 1,200 patients. J Am Acad Dermatol 56 suppl 2 (2007) AB191
10. Doherty S.D., Voorhees A.V., Lebwohl M.G., et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 60 (2009) e21-e22
11. Kimball A.B., Gladman D., Gelfand J.M., et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58 (2008) 1031-1042
12. ®-TB gold test for detecting Mycobacterium tuberculosis infection, United States. (PDF). Morb Mortal Wkly Rep 54 (2005)
13. Chaudhari U., Romano P., Mulcahy L.D., et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357 (2001) 1842-1846
14. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
15. Lim W.S., Powell R.J., Johnston I.D., et al. Tuberculosis and treatment with infliximab (multiple letters). N Engl J Med 346 (2002) 623-626
16. Scheinfeld N.A. Comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab, and adalimumab. J Dermatol Treat 15 (2004) 280-294
17. Schmitt J., and Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics 3 (2009) 303-318
18. Huang W., Cordoro K.M., Taylor S.L., et al. To test or not to test?. An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol 58 (2008) 970-977
19. Infliximab (Remicade) [package insert] (2006), PA, Centocor Inc, Malvern
20. Khanna M., Shirodkar M.A., and Gottlieb A.B. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat 14 (2003) 229-232
21. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004) 580-584
22. Peterson J.R., Hsu F.C., Simkin P.A., et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
23. Brimhall A.K., King L.N., Licciardone J.C., et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 159 (2008) 274-285
24. Fulchiero G.J., Salvaggio H., Drabick J.J., et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 56 (2007) S65-S67
25. Brown S.L., Greene M.H., Gershon S.K., et al. Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum 46 (2002) 3151-3158
26. Emery P., Fleischmann R.M., Moreland L.W., et al. Golimumab, a human Anti-tumor Necrosis Factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60 (2009) 2272-2283
27. Smolen J.S., Kay J., Doyle M.K., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (go-after study): a multicentre, randomized, double-blind, placebo controlled, phase III trial. Lancet 374 (2009) 210-221
28. Askling J., Fored S.M., Baecklund E., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1414-1420
29. Aboulafia D.M., Bundow D., Wilske K., et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 75 (2000) 1093-1098
30. Slifman N.R., Gershon S.K., Lee J.H., et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alphaneutralizing agents. Arthritis Rheum 48 (2003) 319-324
31. Lee J.H., Slifman N.R., Gershon S.K., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46 (2002) 2565-2570
32. Wallis R., Broder M., Wong Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
33. Wallis R., Broder M., Wong Y., et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39 (2004) 1256
34. Ramos-Casals M., Brito-Zerón P., Soto M.J., et al. Autoimmune diseases induced by TNFΑ-targeted therapies. Best Pract Res Clin Rheumatol 22 (2008) 847-861
35. Kerbleski J.F., and Gottlieb A.B. Dermatological complications and safety of anti-TNF treatments. Gut 58 (2009) 1033-1039
36. Mohan A.K., Edwards E.T., Cote T.R., et al. Drug-induced systemic lupus erythematosus and TNFΑ-alpha blockers. Lancet 360 (2002) 646
37. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s000lbl.pdf
38. Smith C.H., Anstey A.V., Barker J.N., et al. British association of dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 161 (2009) 987-1019
39. Gottlieb A., Menter A., Mendelsohn A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial. Lancet 373 (2009) 633-640
40. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 2). Lancet 371 (2008) 1675-1684
41. Major E.O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61 (2009) 35-47
42. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (Phoenix 1). Lancet 371 (2008) 1665-1674
43. http://www.fda.gov/downloads/Drugs/DrugSafety/.../UCM188457.pdf
44. Patel R.V., Clark L.N., Lebwohl M., et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 60 (2009) 1001-1017
45. Golda N., Benham S.M., and Koo J. Rebound of psoriasis during treatment with efalizumab. J Drugs Dermatol 5 (2006) 63-65
46. Rallis E, Korfitis C, Stavropoulou E, et al: Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a "class effect" of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J Dermatol Treat (in press)
47. Wollina U., Hansel G., Koch A., et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9 (2008) 1-14
48. Papadavid E., Gazi S., Dalamaga M., et al. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol 22 (2008) 380-382
49. Papp K.A., Toth D., and Rosoph L. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatol 6 (2006) 9
50. Kocharla L., and Mongey A.B. Is the development of drug-related lupus a contraindication for switching from one TNFΑ alpha inhibitor to another?. Lupus 18 (2009) 169-171
51. Hyrich K.L., Lunt M., Watson K.D., et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large uk national cohort study. Arthritis Rheum 56 (2007) 13-20
52. Simister N.E. Placental transport of immunoglobulin G. Vaccine 21 (2003) 3365-3369
53. Chambers C.D., Johnson D.L., and Jones K.L. Pregnancy outcome in women exposed to anti-TNF alpha medications: the otis rheumatoid arthritis in pregnancy study. Arthritis Rheum 50 (2004) S479
54. Chambers C.D. Safety of anti-TNF alpha medications in pregnancy. J Am Acad Dermatol 52 suppl 2 (2005) AB8 155-108